Evidence from randomized clinical trials demonstrating improved glycemic control with GLP-1 receptor agonists when used with other agents vs other combination therapy strategies

Defronzo, 2009, Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus, Diabetes, 58, 773, 10.2337/db09-9028 Nathan, 2006, Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 29, 1963, 10.2337/dc06-9912 Fonseca, 2009, Defining and characterizing the progression of type 2 diabetes, Diabetes Care, 32, S151, 10.2337/dc09-S301 Drucker, 2003, Enhancing incretin action for the treatment of type 2 diabetes, Diabetes Care, 26, 2929, 10.2337/diacare.26.10.2929 Nauck, 1986, Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses, J Clin Endocrinol Metab, 63, 492, 10.1210/jcem-63-2-492 Nauck, 1986, Reduced incretin effect in type 2 (non-insulin-dependent) diabetes, Diabetologia, 29, 46, 10.1007/BF02427280 Inzucchi, 2012, Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care, 10.2337/dc12-0413 Drucker, 2006, The biology of incretin hormones, Cell Metab, 3, 153, 10.1016/j.cmet.2006.01.004 Holst, 2008, Glucagon-like peptide-1, glucose homeostasis and diabetes, Trends Mol Med, 14, 161, 10.1016/j.molmed.2008.01.003 Drucker, 2006, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, Lancet, 368, 1696, 10.1016/S0140-6736(06)69705-5 Drucker, 2006, Enhancing the action of incretin hormones: a new whey forward?, Endocrinology, 147, 3171, 10.1210/en.2006-0494 Davidson, 2010, Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors, Mayo Clin Proc, 85, S27, 10.4065/mcp.2010.0469 Scheen, 2012, A review of gliptins in 2011, Expert Opin Pharmacother, 13, 81, 10.1517/14656566.2012.642866 Freeman, 2012, Common patient concerns about the use of glucagon-like peptide-1 receptor agonists in diabetes mellitus management, J Am Osteopath Assoc, 112, S22 Rodbard, 2009, Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control, Endocr Pract, 15, 540, 10.4158/EP.15.6.540 Nathan, 2009, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 32, 193, 10.2337/dc08-9025 Rodbard, 2009, Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control, Endocr Pract, 15, 540, 10.4158/EP.15.6.540 Handelsman, 2011, American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan, Endocr Pract, 17, 1, 10.4158/EP.17.S2.1 Esposito, 2011, GLP-1 receptor agonists and HBA1c target of<7% in type 2 diabetes: meta-analysis of randomized controlled trials, Curr Med Res Opin, 27, 1519, 10.1185/03007995.2011.590127 Deacon, 2012, Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis, Diabetes Obes Metab, 10.1111/j.1463-1326.2012.01603.x Vilsboll, 2012, Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials, Br Med J, 344, d7771, 10.1136/bmj.d7771 Zinman, 2009, Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 met + TZD), Diabetes Care, 32, 1224, 10.2337/dc08-2124 Riddle, 2006, Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin, Diabetes Metab Res Rev, 22, 483, 10.1002/dmrr.646 Russell-Jones, 2009, Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial, Diabetologia, 52, 2046, 10.1007/s00125-009-1472-y Heine, 2005, Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial, Ann Intern Med, 143, 559, 10.7326/0003-4819-143-8-200510180-00006 Diamant, 2012, Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks, Diabetes Care, 35, 683, 10.2337/dc11-1233 Arnolds, 2010, Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study, Diabetes Care, 33, 1509, 10.2337/dc09-2191 Buse, 2011, Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial, Ann Intern Med, 154, 103, 10.7326/0003-4819-154-2-201101180-00300 Bergenstal, 2010, Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial, Lancet, 376, 431, 10.1016/S0140-6736(10)60590-9 Wysham, 2011, DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide, Diabet Med, 28, 705, 10.1111/j.1464-5491.2011.03301.x Pratley, 2011, One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial, Int J Clin Pract, 65, 397, 10.1111/j.1742-1241.2011.02656.x Pratley, 2010, Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial, Lancet, 375, 1447, 10.1016/S0140-6736(10)60307-8 Davies, 2011, Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metformin, Diabet Med, 28, 333 Best, 2011, Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment, Diabetes Care, 34, 314, 10.2337/dc10-1119 DeYoung, 2011, Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes, Diabetes Technol Ther, 13, 1145, 10.1089/dia.2011.0050 Drucker, 2008, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study, Lancet, 372, 1240, 10.1016/S0140-6736(08)61206-4 Blevins, 2011, DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes, J Clin Endocrinol Metab, 96, 1301, 10.1210/jc.2010-2081 Aroda, 2011, Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes, Postgrad Med, 123, 228, 10.3810/pgm.2011.09.2479 Buse, 2009, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6), Lancet, 374, 39, 10.1016/S0140-6736(09)60659-0 Buse, 2010, Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents, Diabetes Care, 33, 1300, 10.2337/dc09-2260 Buse, 2012, Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study, Lancet Verges, 2011, Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system, Diabetes Metab, 37, 477, 10.1016/j.diabet.2011.07.001 Courreges, 2008, Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes, Diabet Med, 25, 1129, 10.1111/j.1464-5491.2008.02484.x Klonoff, 2008, Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years, Curr Med Res Opin, 24, 275, 10.1185/030079908X253870 Bunck, 2010, Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition, Diabetes Care, 33, 1734, 10.2337/dc09-2361 Fonseca, 2011, Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus, Am J Cardiol, 108, 52B, 10.1016/j.amjcard.2011.03.016